US · biotechnology · gene therapy · healthcare
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series B · Jun 2026 · $125M
ARCH Venture Partners lead, Perceptive Advisors lead, F-Prime Capital, Venrock, Alexandria Venture Investments, Bristol Myers Squibb, Johnson & Johnson Innovation, Eli Lilly and Company
Reported by Ventureburn · SEC filing: $125M sold under the offering
Missing a round, or an investor who was in one? Tell us.